ClinicalTrials.gg
TerminatedNCT00857649Updated Dec 5, 2013Results posted

Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease

A Phase 3 interventional study of Memantine and Placebo in Alzheimer's Disease, sponsored by H. Lundbeck A/S. Terminated at 23 sites in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2013-12-05.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
369
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing memantine in Alzheimer Disease — 1 open to participants now, 2 under way, none of them phase 3. Memantine · Alzheimer Disease.

Enrollment
4th of 34
369 · median 90
Started
2003
with 1 other
Phase 3
8 of 34
none open now
Registered
18th of 34
by date
Lead sponsor
4 of 34
H. Lundbeck A/S

Among the 34 studies testing memantine in Alzheimer Disease, this one is the 4th largest by enrollment, is one of 2 that started in 2003, is one of 8 in phase 3, and was the 18th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 34 studies testing memantine in Alzheimer Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About memantine

Memantine: first FDA approval 2003 (NAMENDA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing memantine in Alzheimer Disease, or all of them as a file.
02

Study summary

The primary objective of this study is to examine the efficacy of memantine on cognition and behavioural symptoms in outpatients with moderate to severe dementia of the Alzheimer's type.

Read the detailed description

Memantine is a moderate affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. Pre-clinical studies have demonstrated that memantine can decrease the neuronal toxicity associated with excessive glutamate release and calcium overload in neurons. Results from clinical trials in patients with moderate to severe Alzheimer's Disease (AD) have demonstrated memantine's efficacy and safety by showing positive treatment effects on cognitive, global and functional decline.

This 24-week randomised, double-blind, placebo-controlled, multicentre study examines the effect of memantine 20 mg, administered once daily, on cognitive and behavioural symptoms in outpatients diagnosed with moderate to severe AD and significant psychopathology.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Alzheimer's Disease
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Outpatients who:

  • had a primary diagnosis of probable Alzheimer's Disease (AD) according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINDS-ADRDA) criteria, and with , 4th edition, text revised (DSM IV TR) criteria for dementia of the Alzheimer's type
  • had moderate to severe dementia, defined as a (MMSE) total score >=5 and \<=15 at screening. Before substantial protocol amendment SA04 (dated 7 October 2004) was implemented, the MMSE total score range at screening was >=8 and \<=18. Substantial protocol amendment SA07 (dated 4 September 2009) allowed patients who had previously had an MMSE score of 16 or 17 to be re-screened >6 months after their initial screening and, if there was documented evidence of cognitive decline, to be enrolled in the study
  • had a Neuropsychiatric Inventory (NPI) total score >=13 and an NPI agitation/aggression subitem score >=1 at screening and baseline
  • did not have vascular dementia or a modified Hachinski Ischaemia Scale score >4 at screening

Exclusion criteria

Exclusion Criteria:

  • Evidence of active disease, evidence of other neurological disorders, and previous treatment with memantine
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
369 participants (actual)

Study arms

  • Experimental
    Memantine

    Drug: Memantine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 20 mg Oral Tablets Once Daily

    Also known as: Ebixa®

  • DrugPlacebo

    Oral Tablets Once Daily

06

What researchers measure

Primary outcomes

  1. Efficacy of Memantine on Behavioural Symptoms in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the NPI - 12 Items Version Total Score.

    Change from Baseline in Neuropsychiatric Inventory (NPI) total score. NPI is a validated scale that assesses behavioural disturbances in patients with dementia. The 12 item version consists of 10 behavioural and 2 neurovegetative areas. It provides both a total score as well as scores for a number of sub-scales. The frequency, severity and caregiver distress for each domain are measured. The NPI is based upon responses obtained from the caregiver. The total score is from 0 to 144. A higher score reflects more frequency and severity of the disturbances.

    Time frame: Baseline to Week 24

  2. Efficacy of Memantine on Cognition in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the SIB Total Score.

    Change from Baseline in Severe Impairment Battery (SIB) total score. SIB is a validated scale used to assess cognitive function in patients with moderate to severe dementia. Items are single words or one-step commands combined with gestures. Nine domains are assessed, and the total score is between 0 and 100. A lower total score reflects the loss of cognitive function.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Efficacy of Memantine on Global Condition Using CIBIC-plus.

    Clinician's Interview-Based Impression of Change-Plus Version (CIBIC-plus). Improvement evaluated with reference to Baseline. CIBIC-plus is a global rating that is derived through an independent, comprehensive interview with the patient and caregiver by a rater who is barred from knowledge of all other psychometric test scores conducted as part of this protocol as well as from reported safety data. The rating is made on a 7-point scale ranging from "1 = marked improvement" to "7 = marked worsening". A score of "4" indicates no change.

    Time frame: Baseline to Week 24

  2. Efficacy of Memantine on Functioning Using ADCS-ADL - 19 Items Total Score.

    Change from Baseline on the Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) 19-item version total score. ADCS-ADL- 19 items version for moderate to severe AD will measure patient's functioning. This battery of ADL questions is used here to measure the functional capabilities of patients with dementia. The inventory is done by interviewing a person in close contact with the patient and covers the most usual and consistent performance of the patient over the preceding 4 weeks. Total score is from 0 to 54. The higher score, the lower impairment.

    Time frame: Baseline to Week 24

  3. Efficacy of Memantine on Functioning Using CMAI - Long Form Total Score.

    Change from Baseline on the Cohen-Mansfield Agitation Inventory (CMAI) - Long Form total score. CMAI - Long Form looks specifically at agitated behaviour in patients with cognitive impairment. It is a seven-point rating scale assessing the frequency of up to 29 agitated behaviours, ranging from "1 = Never" to "7 = Several times an hour". Rating is based on responses obtained from interviews with the caregiver. The total score ranges from 29 to 203, with a higher score reflecting more frequent behavioural disturbances.

    Time frame: Baseline to Week 24

07

Results

Posted Jan 9, 2012
Limitations and caveats
Long recruitment, premature termination, substantial protocol changes; baseline imbalances (concomitant medication and severity of agitation). Variability across sites in reported events frequency (50% of agitation reports from a single site)

Participant flow

The patients were recruited from the investigators' outpatient clinics.

Participant flow — Overall Study
MilestoneMemantinePlacebo
Started182187
Completed151155
Not completed3132
Withdrew: Adverse event1510
Withdrew: Non-compliance11
Withdrew: Protocol violation22
Withdrew: Withdrawal of consent107
Withdrew: Nursing home placement29
Withdrew: Other reasons13

Outcome measures

PrimaryEfficacy of Memantine on Behavioural Symptoms in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the NPI - 12 Items Version Total Score.

Change from Baseline in Neuropsychiatric Inventory (NPI) total score. NPI is a validated scale that assesses behavioural disturbances in patients with dementia. The 12 item version consists of 10 behavioural and 2 neurovegetative areas. It provides both a total score as well as scores for a number of sub-scales. The frequency, severity and caregiver distress for each domain are measured. The NPI is based upon responses obtained from the caregiver. The total score is from 0 to 144. A higher score reflects more frequency and severity of the disturbances.

Time frame:
Baseline to Week 24
Reported as:
Mean · Scores on a scale
Efficacy of Memantine on Behavioural Symptoms in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the NPI - 12 Items Version Total Score.
Scores on a scaleMemantinePlacebo
Efficacy of Memantine on Behavioural Symptoms in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the NPI - 12 Items Version Total Score.-3.90 ± 1.24-5.13 ± 1.23
Statistical analysis
  • Memantine vs Placebo · ANCOVA · p = 0.418 · Mean difference (final values): 1.23 · 95% CI -1.75 to 4.21Centre and treatment as factors and baseline score as covariate. Estimate based on Least Squares.
PrimaryEfficacy of Memantine on Cognition in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the SIB Total Score.

Change from Baseline in Severe Impairment Battery (SIB) total score. SIB is a validated scale used to assess cognitive function in patients with moderate to severe dementia. Items are single words or one-step commands combined with gestures. Nine domains are assessed, and the total score is between 0 and 100. A lower total score reflects the loss of cognitive function.

Time frame:
Baseline to Week 24
Reported as:
Mean · Scores on a scale
Efficacy of Memantine on Cognition in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the SIB Total Score.
Scores on a scaleMemantinePlacebo
Efficacy of Memantine on Cognition in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the SIB Total Score.-2.34 ± 0.76-1.86 ± 0.75
Statistical analysis
  • Memantine vs Placebo · ANCOVA · p = 0.603 · Mean difference (final values): -0.48 · 95% CI -2.30 to 1.34Centre and treatment as factors and baseline score as covariate. Estimate based on Least Squares.
SecondaryEfficacy of Memantine on Global Condition Using CIBIC-plus.

Clinician's Interview-Based Impression of Change-Plus Version (CIBIC-plus). Improvement evaluated with reference to Baseline. CIBIC-plus is a global rating that is derived through an independent, comprehensive interview with the patient and caregiver by a rater who is barred from knowledge of all other psychometric test scores conducted as part of this protocol as well as from reported safety data. The rating is made on a 7-point scale ranging from "1 = marked improvement" to "7 = marked worsening". A score of "4" indicates no change.

Time frame:
Baseline to Week 24
Reported as:
Mean · Scores on a scale
Efficacy of Memantine on Global Condition Using CIBIC-plus.
Scores on a scaleMemantinePlacebo
Efficacy of Memantine on Global Condition Using CIBIC-plus.4.68 ± 0.114.63 ± 0.11
Statistical analysis
  • Memantine vs Placebo · ANCOVA · p = 0.734 · Mean difference (final values): 0.05 · 95% CI -0.22 to 0.31Centre and treatment as factors and baseline score as covariate. Estimate based on Least Squares.
SecondaryEfficacy of Memantine on Functioning Using ADCS-ADL - 19 Items Total Score.

Change from Baseline on the Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) 19-item version total score. ADCS-ADL- 19 items version for moderate to severe AD will measure patient's functioning. This battery of ADL questions is used here to measure the functional capabilities of patients with dementia. The inventory is done by interviewing a person in close contact with the patient and covers the most usual and consistent performance of the patient over the preceding 4 weeks. Total score is from 0 to 54. The higher score, the lower impairment.

Time frame:
Baseline to Week 24
Reported as:
Mean · Scores on a scale
Efficacy of Memantine on Functioning Using ADCS-ADL - 19 Items Total Score.
Scores on a scaleMemantinePlacebo
Efficacy of Memantine on Functioning Using ADCS-ADL - 19 Items Total Score.-4.36 ± 0.67-2.56 ± 0.65
Statistical analysis
  • Memantine vs Placebo · ANCOVA · p = 0.017 · Mean difference (final values): -1.80 · 95% CI -3.29 to -0.32Centre and treatment as factors and baseline score as covariate. Estimate based on Least Squares.
SecondaryEfficacy of Memantine on Functioning Using CMAI - Long Form Total Score.

Change from Baseline on the Cohen-Mansfield Agitation Inventory (CMAI) - Long Form total score. CMAI - Long Form looks specifically at agitated behaviour in patients with cognitive impairment. It is a seven-point rating scale assessing the frequency of up to 29 agitated behaviours, ranging from "1 = Never" to "7 = Several times an hour". Rating is based on responses obtained from interviews with the caregiver. The total score ranges from 29 to 203, with a higher score reflecting more frequent behavioural disturbances.

Time frame:
Baseline to Week 24
Reported as:
Mean · Scores on a scale
Efficacy of Memantine on Functioning Using CMAI - Long Form Total Score.
Scores on a scaleMemantinePlacebo
Efficacy of Memantine on Functioning Using CMAI - Long Form Total Score.-0.26 ± 0.79-1.16 ± 0.79
Statistical analysis
  • Memantine vs Placebo · ANCOVA · p = 0.360 · Mean difference (final values): 0.90 · 95% CI -1.03 to 2.83Centre and treatment as factors and baseline score as covariate. Estimate based on Least Squares.

Adverse events

Collected over Up to 28 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Memantine—18/182 (9.9%)51/182 (28%)
Placebo—11/187 (5.9%)35/187 (18.7%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventMemantinePlacebo
UrosepsisInfections and infestations2/1820/187
FallInjury, poisoning and procedural complications2/1820/187
AnaemiaBlood and lymphatic system disorders0/1822/187
Atrial fibrillationCardiac disorders1/1820/187
BradyarrhythmiaCardiac disorders1/1820/187
AstheniaGeneral disorders1/1820/187
Local swellingGeneral disorders1/1820/187
Cholecystitis acuteHepatobiliary disorders1/1820/187
Acute sinusitisInfections and infestations1/1820/187
Respiratory tract infection bacterialInfections and infestations1/1820/187
Most frequent other events
Most frequent other events
EventMemantinePlacebo
FallInjury, poisoning and procedural complications19/1828/187
AgitationPsychiatric disorders15/1827/187
Weight decreasedInvestigations11/1825/187
NauseaGastrointestinal disorders4/18211/187
SomnolenceNervous system disorders10/1825/187

Baseline characteristics

Age Continuous
Age Continuous(years)MemantinePlaceboTotal
Mean74.7 ± 7.975.1 ± 6.974.9 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)MemantinePlaceboTotal
Female105110215
Male7777154
NPI: Baseline Total Score
NPI: Baseline Total Score(Scores on a scale)MemantinePlaceboTotal
Mean30.9 ± 14.829.2 ± 13.330.1 ± 14.0
SIB: Baseline Total Score
SIB: Baseline Total Score(Scores on a scale)MemantinePlaceboTotal
Mean82.3 ± 14.682.0 ± 12.982.1 ± 13.7
CIBIC-plus: Baseline Severity Score
CIBIC-plus: Baseline Severity Score(Scores on a scale)MemantinePlaceboTotal
Mean4.4 ± 0.94.4 ± 0.94.4 ± 0.9
ADCS-ADL - 19 items: Baseline Total Score
ADCS-ADL - 19 items: Baseline Total Score(Scores on a scale)MemantinePlaceboTotal
Mean35.3 ± 9.936.4 ± 8.635.8 ± 9.3
CMAI - Long Form: Baseline Total Score
CMAI - Long Form: Baseline Total Score(Scores on a scale)MemantinePlaceboTotal
Mean46.8 ± 10.947.0 ± 10.946.9 ± 10.9
08

Study locations

23 sites
  • CA019
    Edmonton, Alberta T5G 0B7, Canada
  • CA033
    Kelowna, British Columbia V1W 4V5, Canada
  • CA034
    Winnipeg, Manitoba R3M 0X9, Canada
  • CA022
    St. John, New Brunswick, Canada
  • CA046
    Kentville, Nova Scotia B4N 4K9, Canada
  • CA045
    Pictou, Nova Scotia B0K 1H0, Canada
  • CA032
    Burlington, Ontario L7M 4Y1, Canada
  • CA029
    Orangeville, Ontario L9W 2E1, Canada
  • CA004
    Ottawa, Ontario K1N 5C8, Canada
  • CA038
    Peterborough, Ontario K9H 2P4, Canada
  • CA009
    Toronto, Ontario M3B 2W7, Canada
  • CA037
    Windsor, Ontario N8X 5A6, Canada
  • CA005
    Beauport, Quebec G1J 2G3, Canada
  • CA023
    Greenfield Park, Quebec J4V 2J2, Canada
  • CA013
    Montreal, Quebec H1T 2M4, Canada
  • CA031
    Sherbrooke, Quebec J1J 2B8, Canada
  • CA012
    Sherbrooke, Quebec J1J 3H5, Canada
  • CA030
    Vanier, Quebec G1M 2R9, Canada
  • CA017
    Verdun, Quebec H4H 1R3, Canada
  • CA015
    Regina, Saskatchewan S4T 1A5, Canada
  • CA040
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • CA043
    Kelowna, V1Y 3G8, Canada
  • CA042
    Penticton, V2A 5C8, Canada
09

References and documents

Publications

  • Herrmann N, Gauthier S, Boneva N, Lemming OM; 10158 Investigators. A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. Int Psychogeriatr. 2013 Jun;25(6):919-27. doi: 10.1017/S1041610213000239. Epub 2013 Mar 8. PubMed 23472619 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003, a primary completion of Apr 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2009
First posted
Mar 6, 2009
Start
Dec 2003
Primary completionActual
Apr 2010
CompletionActual
Sep 2010
Results first posted
Jan 9, 2012
Last update
Dec 5, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00857649
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Mar 6, 2009
Start date
Dec 2003
Primary completion
Apr 2010
Completion
Sep 2010
Results posted
Jan 9, 2012
Last update
Dec 5, 2013

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Memantine

Start the discussion